Ensysce Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 9
- Market Cap
- $5.4M
- Website
- http://www.ensysce.com
- Introduction
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, ta...
Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)
- First Posted Date
- 2024-10-07
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 16
- Registration Number
- NCT06629402
- Locations
- 🇺🇸
Dr. Vince Clinical Research, Overland Park, Kansas, United States
PF614 Analgesic Activity in Acute Postoperative Pain
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 300
- Registration Number
- NCT06602271
Single and Multi-Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 50
- Registration Number
- NCT06500793
- Locations
- 🇺🇸
Quotient Sciences, Miami, Florida, United States
A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users
- Conditions
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 32
- Registration Number
- NCT05571345
- Locations
- 🇺🇸
Dr. Vince Clinical Research, Overland Park, Kansas, United States
A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 27
- Registration Number
- NCT05567354
- Locations
- 🇺🇸
Ohio Clinical Trails, Columbus, Ohio, United States
Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 111
- Registration Number
- NCT05090280
- Locations
- 🇺🇸
Quotient Sciences, Miami, Florida, United States
Evaluation of Oral PF614 Relative to OxyContin
- Conditions
- Interventions
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 84
- Registration Number
- NCT05043766
- Locations
- 🇺🇸
PRA Health Sciences-Early Development Services, Salt Lake City, Utah, United States
Oral Nafamostat in Healthy Volunteers
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 17
- Registration Number
- NCT04406415
- Locations
- 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)
- Conditions
- Interventions
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 64
- Registration Number
- NCT02454712
- Locations
- 🇺🇸
PRA Health Sciences - Early Development Services, Lenexa, Kansas, United States